Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 237 clinical trials
Featured trial
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Aflibercept, Compared With Aflibercept Alone, in Participants With nAMD

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Aflibercept, Compared With Aflibercept Alone, in Participants With nAMD

  • 0 views
  • 10 Mar, 2022
  • 1 location
Featured trial
Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration- CEDAR STUDY

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration- CEDAR STUDY

  • 1138 views
  • 23 Nov, 2020
  • 1 location
OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (ShORe)

A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

  • 10 views
  • 12 May, 2022
  • 99 locations
OPT-302 With Aflibercept in Neovascular Age-related Macular Degeneration (nAMD) (COAST)

A 2-year phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.

  • 28 views
  • 14 May, 2022
  • 90 locations
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (AVONELLE-X)

treatment interval to participants with neovascular age-related macular degeneration who enrolled in and completed one of the Phase III studies: GR40306 (NCT03823287) or GR40844 (NCT03823300), also referred

  • 0 views
  • 30 Apr, 2022
  • 33 locations
Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration (Mylight)

Purpose and rationale: To demonstrate similar efficacy, safety and immunogenicity of SOK583A1 and Eylea EU as per Eylea approved treatment regimen in patients with nAMD. The primary clinical question of interest is: Does SOK583A1 have similar efficacy as Eylea EU in terms of mean change in BCVA score in participants …

  • 139 views
  • 02 May, 2022
  • 105 locations
A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)

ranibizumab (PDS) 100 mg/mL delivered every 36 weeks (Q36W) compared with every 24 weeks (Q24W) in patients with neovascular age-related macular degeneration (nAMD).

  • 0 views
  • 03 May, 2022
  • 51 locations
RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration (TEMPURA)

This study is a single-center, open label, 4-month study, designed to evaluate the safety and treatment efficacy of RBM-007 in patients with intraretinal or subretinal edema due to previously untreated neovascular AMD. Up to 5 subjects will be randomized to receive study medication. Study treatment will be administered by intravitreal …

corrected visual acuity
edema
neovascularization
  • 10 views
  • 12 Mar, 2022
  • 1 location
Connection Between Periodontitis and Exudative Age-related Macular Degeneration (FLAREPARO)

as periodontitis, increase aqueous flare and possibly activates exudative age-related macular degeneration.

anti-infective
Accepts healthy volunteers
  • 120 views
  • 28 Feb, 2022
  • 1 location
A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration

The purpose of this study is to assess the effect of Iptacopan to prevent conversion of early or intermediate age-related macular degeneration (AMD) eyes to new incomplete retinal pigment

retinal pigment
atrophy
optical coherence tomography
  • 0 views
  • 08 Apr, 2022
  • 2 locations